What is the 13F Pro Quality Score for VSTM?

13F Pro ranks Verastem, Inc. (VSTM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VSTM's current score at https://13fpro.ai/research/VSTM (free sign-up required for the full ranking).

Which hedge funds own the most VSTM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of VSTM include RTW INVESTMENTS,, BlackRock,, Deep Track Capital,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/VSTM as soon as new 13F filings post.

Where does 13F Pro source VSTM data?

All Verastem, Inc. fundamentals and ownership data come directly from SEC EDGAR. Verastem, Inc. files with the SEC under CIK 1526119. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VSTM in?

Verastem, Inc. (VSTM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VSTM research updated on 13F Pro?

VSTM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Verastem, Inc.(VSTM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1526119 VSTM stock profile & AI dashboard →

13F Pro Quality Score

40.8/100

Rank #1,921 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

97.5/100

Profitability

30.0/100

Balance Sheet

1.0/100

Earnings Quality

30.0/100

Free Cash Flow

30.0/100

Institutional Flow

87.3/100

Revenue Scale

30.0/100

Dilution Risk

6.5/100

VSTM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Verastem, Inc. (VSTM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VSTM at 40.8/100 on a 32-signal composite quality model, placing it at rank #1,921 of 2,879 stocks — the bottom half of the AI-ranked universe. VSTM scores in the top quartile across revenue growth (97.5), institutional flow (87.3). Areas of concern include balance sheet strength (1.0) and profitability (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Verastem, Inc. reports quarterly revenue of $18.7M, net income of $-36.6M, free cash flow of $-52.1M. Top institutional holders of VSTM by reported 13-F value include RTW INVESTMENTS,, BlackRock,, Deep Track Capital,, based on the most recent SEC filings. VSTM trades on the Nasdaq exchange and files with the SEC under CIK 1526119. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VSTM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Verastem, Inc. directly from SEC EDGAR. Verastem, Inc.'s 13F Pro composite quality score has ranged between 7 and 43 since 2021, currently 40.8 — an improving long-term trajectory across 24 quarterly and live scoring snapshots.

✦

Fun facts about Verastem, Inc.

Quirks, history, and lore behind VSTM — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap U.S. biopharmaceutical company listed on Nasdaq, focused on developing targeted cancer therapies.
2
The Numbers
Revenue is modest for a clinical-stage biotech — think tens of millions at best — with the balance sheet leaning heavily on equity raises to fund ongoing trials.
3
The History
Founded in the early 2010s, the company pivoted its pipeline over time to concentrate on RAS/MAPK pathway inhibitors, chasing some of oncology's most notoriously hard-to-drug targets.
4
The Secret
Its lead program combines a RAF inhibitor and a MEK inhibitor in a doublet aimed at low-grade serous ovarian cancer — a rare tumor with very few approved options.
5
The Lore
The company's name is a mashup evoking truth (Latin: vera) and the concept of a stem cell, nodding to its original scientific roots before the RAS pivot.
6
The Giveaway
Ticker VSTM, headquartered in Boston, and best known for its avutometinib + defactinib combo targeting ovarian cancer — this one's for the oncology deep-divers.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$18.7M

Net Income

Q1 2026

$-36.6M

Free Cash Flow

Q1 2026

$-52.1M

ROIC

Q1 2026

-54.9%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+209.1% YoY

$30.9MFY 2025

FY22 $2.6MFY23 —FY24 $10.0MFY25 $30.9M

Net Income

-60.3% YoY

$-209.5MFY 2025

FY22 $-73.8MFY23 $-87.4MFY24 $-130.6MFY25 $-209.5M

Operating Income

-48.0% YoY

$-170.1MFY 2025

FY22 $-72.9MFY23 $-92.1MFY24 $-115.0MFY25 $-170.1M

EPS (Diluted)

+17.5% YoY

$-3.02FY 2025

FY22 $-0.38FY23 $-3.96FY24 $-3.66FY25 $-3.02

Total Assets

+142.7% YoY

$246.4MFY 2025

FY22 $95.0MFY23 $149.7MFY24 $101.5MFY25 $246.4M

Total Debt

—FY 2025

FY22 $24.5MFY23 $40.1MFY24 $40.7MFY25 —

Op. Cash Flow

-31.2% YoY

$-137.5MFY 2025

FY22 $-63.7MFY23 $-86.5MFY24 $-104.8MFY25 $-137.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$30.9M +209.1%	$10.0M	—	$2.6M +26.4%	$2.1M -97.7%	$88.5M
Net Income	$-209.5M -60.3%	$-130.6M -49.5%	$-87.4M -18.4%	$-73.8M -3.7%	$-71.2M -5.1%	$-67.7M
Operating Income	$-170.1M -48.0%	$-115.0M -24.8%	$-92.1M -26.3%	$-72.9M -18.8%	$-61.4M -24.4%	$-49.4M
EPS (Diluted)	$-3.02 +17.5%	$-3.66 +7.6%	$-3.96 -939.9%	$-0.38 +6.7%	$-0.41 -1012.5%	$-0.04
Total Assets	$246.4M +142.7%	$101.5M -32.2%	$149.7M +57.5%	$95.0M -12.5%	$108.7M -29.6%	$154.3M
Total Debt	—	$40.7M +1.6%	$40.1M +63.4%	$24.5M	—	—
Operating Cash Flow	$-137.5M -31.2%	$-104.8M -21.2%	$-86.5M -35.8%	$-63.7M -19.0%	$-53.5M -59.7%	$-33.5M

AI Insight: VSTM Financial Trends

Revenue grew from $10M in Q2 2024 to $19M in Q1 2026, but equity remains volatile swinging from -$32M to $82M across quarters.

• Revenue increased from $10M in Q2 2024 to $19M in Q1 2026, showing growth momentum.

• Operating losses remained consistently high, ranging from -$32M to -$46M across all quarters.

• Total debt held steady at $41M from Q4 2024 through Q4 2025 before disappearing in Q1 2026.

⚠ Operating cash flow worsened from -$30M in Q4 2025 to -$52M in Q1 2026.

⚠ Equity swings dramatically between quarters, from -$32M to $82M, indicating potential volatility in funding.

AI Insight: VSTM Ratio Trends

Verastem shows deteriorating profitability with ROA declining from -52.9% in Q2 2025 to -64.2% in Q1 2026.

• Net profit margin worsened from -187.7% in Q4 2025 to -196.0% in Q1 2026.

• Return on assets declined from -52.9% in Q2 2025 to -64.2% in Q1 2026.

• Debt-to-equity ratio improved from 2.77 in Q3 2024 to 0.71 in Q4 2025.

⚠ ROE turned sharply negative at -179.0% in Q1 2026, first reported figure in the dataset.

⚠ Sparse financial data across multiple quarters limits trend analysis visibility.

Get alerted when VSTM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Verastem, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VSTM

RTW INVESTMENTS, LP
$34.9M6,576,306 sh
BlackRock, Inc.
$32.8M6,194,925 sh
Deep Track Capital, LP
$30.4M5,740,850 sh
ARMISTICE CAPITAL, LLC
$24.3M4,592,000 sh
Nantahala Capital Management, LLC
$19.0M3,584,820 sh
STATE STREET CORP
$18.6M3,516,651 sh
VANGUARD CAPITAL MANAGEMENT LLC
$17.6M3,322,770 sh
Stonepine Capital Management, LLC
$17.5M3,302,300 sh
Foresite Capital Management VI LLC
$16.7M3,146,631 sh
MILLENNIUM MANAGEMENT LLC
$12.8M2,411,965 sh

Fund	Value	Shares
RTW INVESTMENTS, LP	$34.9M	6,576,306
BlackRock, Inc.	$32.8M	6,194,925
Deep Track Capital, LP	$30.4M	5,740,850
ARMISTICE CAPITAL, LLC	$24.3M	4,592,000
Nantahala Capital Management, LLC	$19.0M	3,584,820
STATE STREET CORP	$18.6M	3,516,651
VANGUARD CAPITAL MANAGEMENT LLC	$17.6M	3,322,770
Stonepine Capital Management, LLC	$17.5M	3,302,300
Foresite Capital Management VI LLC	$16.7M	3,146,631
MILLENNIUM MANAGEMENT LLC	$12.8M	2,411,965

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VSTM on your watchlist

Track score changes the day Verastem, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VSTM a good stock to buy?

13F Pro's AI-powered analysis of Verastem, Inc. (VSTM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VSTM are available on the VSTM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VSTM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VSTM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Verastem, Inc.'s investment landscape.